杭州先为达生物科技股份有限公司（临时代码）(91078)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

91078 杭州先为达生物科技股份有限公司（临时代码）

休市中 04-24 16:00:00

0.000

+0.000

--

最高0.000	最低0.000	成交量0.00
今开0.000	昨收0.000	日振幅0.00%
总市值0.00	流通市值0.00	总股本0.00
成交额0.00	换手率--	流通股本0.00
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"91078","market":"HK","secType":"STK","nameCN":"杭州先为达生物科技股份有限公司（临时代码）","latestPrice":0,"timestamp":1777017600000,"preClose":0,"halted":9,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":0,"latestTime":"04-24 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777253400000},"marketStatusCode":7,"adr":0,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1776994200000,1777003200000],[1777006800000,1777017600000]],"volumeRatio":0,"lotSize":100,"spreadScale":0},"requestUrl":"/m/hq/s/91078","defaultTab":"news","newsList":[{"id":"2621381470","title":"先为达生物二次递表港交所；文远知行2025年度总收入同比增长89.6%丨港交所早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2621381470","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621381470?lang=zh_cn&edition=full","pubTime":"2026-03-24 07:05","pubTimestamp":1774307118,"startTime":"0","endTime":"0","summary":"｜2026年3月24日星期二｜NO.1先为达生物二次递表港交所据港交所3月23日消息，杭州先为达生物科技股份有限公司-B（以下简称先为达生物）已向港交所主板递交上市申请。这是该公司第二次递表港交所。据招股书，先为达生物成立于2017年，一直专注于研发先进的体重管理疗法，主要针对肥胖症及相关疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603243681430541.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243681430541.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91078","00012","BK1144","BK1258","02007","BK4124","CTRYY","00800","BK1531","BK1229","BK1104","BK4609","WRD","HLDCY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2621706882","title":"新股消息 | 先为达生物二次递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2621706882","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621706882?lang=zh_cn&edition=full","pubTime":"2026-03-23 20:45","pubTimestamp":1774269920,"startTime":"0","endTime":"0","summary":"据港交所3月23日披露，杭州先为达生物科技股份有限公司-B(简称：先为达生物)向港交所主板递交上市申请书，摩根士丹利、中金公司为其联席保荐人。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260323/20260323204601_42561.png?x-oss-process=image/format,jpg/quality,q_60","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260323/20260323204601_42561.png?x-oss-process=image/format,jpg/quality,q_60"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417610.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["91078","HEXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620947206","title":"新股消息 | 先为达生物港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2620947206","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620947206?lang=zh_cn&edition=full","pubTime":"2026-03-20 10:29","pubTimestamp":1773973775,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，杭州先为达生物科技股份有限公司-B于2025年9月19日所递交的港股招股书满6个月，于2026年3月19日失效，递表时摩根士丹利及中金公司为联席保荐人。据招股书披露，先为达生物是一家接近商业化阶段的生物医药公司，致力于满足体重管理领域的迫切医疗需求。公司即将在中国推出埃诺格鲁肽注射液，该产品有望成为全球首款cAMP偏向型GLP-1受体激动剂，用于治疗超重╱肥胖症及2型糖尿病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416370.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91078","BK4585","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617880683","title":"全球首个偏向型GLP-1减重药获批上市！先为达生物如何用技术管线撑起增长确定性？","url":"https://stock-news.laohu8.com/highlight/detail?id=2617880683","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617880683?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:16","pubTimestamp":1772785014,"startTime":"0","endTime":"0","summary":"重构健康减重逻辑","market":"fut","thumbnail":"https://img2.gelonghui.com/6d428-fb960660-0134-4981-ad6f-fb5f5155f94e.jpg?guru_height=912&guru_width=1613&guru_size=114631","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/6d428-fb960660-0134-4981-ad6f-fb5f5155f94e.jpg?guru_height=912&guru_width=1613&guru_size=114631"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4000644","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4144","BK4590","GLP","91078"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613897750","title":"先为达生物携手辉瑞中国，达成埃诺格鲁肽商业化战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2613897750","media":"市场资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613897750?lang=zh_cn&edition=full","pubTime":"2026-02-24 10:23","pubTimestamp":1771899780,"startTime":"0","endTime":"0","summary":"2月24日消息，杭州先为达生物科技股份有限公司与辉瑞中国今日宣布，双方就新一代偏向型GLP-1受体激动剂埃诺格鲁肽注射液 达成商业化战略合作协议。先为达生物将有权获得辉瑞支付的最高可达4.95亿美元的付款总额，包括首付款、注册及销售里程碑付款。　　埃诺格鲁肽是由先为达生物自主研发的新一代cAMP偏向型GLP-1受体激动剂，将为2型糖尿病及长期体重管理相关患者提供更为精准的治疗方案。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-24/doc-inhnwrqu6119933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0306806265.USD","SGXZ57979304.SGD","LU0234572021.USD","LU0321505868.SGD","LU0321505439.SGD","BK4550","LU1894683348.USD","BK4007","IE00B19Z3581.USD","IE00BLSP4452.SGD","BK4585","SG9999001176.USD","SG9999011175.SGD","SG9999001176.SGD","BK4599","LU0122379950.USD","LU1023059063.AUD","LU0170899867.USD","LU0225771236.USD","BK4581","LU0985481810.HKD","LU0289739699.SGD","LU1894683264.USD","IE00B19Z3B42.SGD","BK4588","LU0456855351.SGD","SG9999002232.USD","IE00BLSP4239.USD","IE0002270589.USD","IE00BBT3K403.USD","BK4568","BK4592","PFE","SG9999002224.SGD","BK4533","LU1066053197.SGD","SG9999013999.USD","BK4534","LU0306807586.USD","LU0225284248.USD","LU1057294990.SGD","LU0868494617.USD","SG9999003800.SGD","91078","LU1066051498.USD","LU0058720904.USD","LU1883839398.USD","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2607091264","title":"全球首个cAMP偏向型GLP-1上市！先为达生物改写赛道格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2607091264","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607091264?lang=zh_cn&edition=full","pubTime":"2026-01-30 15:27","pubTimestamp":1769758036,"startTime":"0","endTime":"0","summary":"先颐达®（埃诺格鲁肽注射液）成功获NMPA批准上市，用于成人2型糖尿病患者的血糖控制，成为全球首个获批上市的cAMP偏向型GLP-1受体激动剂。","market":"sh","thumbnail":"https://img7.gelonghui.com/column/2.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/3726053","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4590","91078","GLP","BK4144"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590050376","title":"新股消息 | 先为达生物拟港股上市 中国证监会要求补充说明已实施的股权激励方案合规性等","url":"https://stock-news.laohu8.com/highlight/detail?id=2590050376","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590050376?lang=zh_cn&edition=full","pubTime":"2025-12-12 19:32","pubTimestamp":1765539141,"startTime":"0","endTime":"0","summary":"中国证监会国际司共对8家企业出具补充材料要求，其中，要求先为达生物补充说明已实施的股权激励方案合规性等事项。据港交所9月19日披露，先为达生物向港交所主板提交上市申请书，摩根士丹利及中金公司为联席保荐人。公司即将在中国推出埃诺格鲁肽注射液，该产品有望成为全球首款cAMP偏向型GLP-1受体激动剂，用于治疗超重/肥胖症及2型糖尿病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["91078"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2576008513","title":"先为达生物IPO：累亏超14亿核心产品市场竞争激烈 创始人多次减持股份投后估值近50亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576008513","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576008513?lang=zh_cn&edition=full","pubTime":"2025-10-17 14:39","pubTimestamp":1760683140,"startTime":"0","endTime":"0","summary":"　　近日，杭州先为达生物科技股份有限公司正式向港交所递交主板上市申请。招股书显示，先为达生物成立于2017年，是一家接近商业化阶段的生物医药公司，专注于针对肥胖症及相关疾病的创新体重管理疗法的研发。　　这家成立八年的生物医药企业，在腾讯、IDG资本、美团、正心谷资本等知名机构的多轮投资加持下，最新估值已高达49亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-10-17/doc-infuetkq8720872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91078"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2571955873","title":"新股前瞻：借势GLP-1风口，先为达生物能否叩开港交所大门？","url":"https://stock-news.laohu8.com/highlight/detail?id=2571955873","media":"智通财经","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571955873?lang=zh_cn&edition=full","pubTime":"2025-09-30 09:42","pubTimestamp":1759196525,"startTime":"0","endTime":"0","summary":"近日，据港交所披露，杭州先为达生物科技股份有限公司-B正式向港交所主板提交上市申请书，联席保荐人为摩根士丹利及中金公司。在国际化布局方面，先为达生物亦在稳步推进。GLP-1赛道竞争日趋激烈随着全民健康意识的不断增强，“体重管理”正日益成为社会关注的焦点，并逐步发展为一个规模持续扩大的独立市场。目前，国内GLP-1药物市场主要由诺和诺德与礼来两家跨国药企主导。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1351056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91078","BK4144","BK4590"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0.0253},{"period":"3month","weight":-0.0288},{"period":"6month","weight":-0.007},{"period":"1year","weight":0.1857},{"period":"ytd","weight":0.0136}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"exchange":"SEHK","name":"杭州先为达生物科技股份有限公司（临时代码）","nameEN":"Hangzhou Sciwind Biosciences Co., Ltd. - B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"杭州先为达生物科技股份有限公司（临时代码）(91078)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供杭州先为达生物科技股份有限公司（临时代码）(91078)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"杭州先为达生物科技股份有限公司（临时代码）,91078,杭州先为达生物科技股份有限公司（临时代码）股票,杭州先为达生物科技股份有限公司（临时代码）股票老虎,杭州先为达生物科技股份有限公司（临时代码）股票老虎国际,杭州先为达生物科技股份有限公司（临时代码）行情,杭州先为达生物科技股份有限公司（临时代码）股票行情,杭州先为达生物科技股份有限公司（临时代码）股价,杭州先为达生物科技股份有限公司（临时代码）股市,杭州先为达生物科技股份有限公司（临时代码）股票价格,杭州先为达生物科技股份有限公司（临时代码）股票交易,杭州先为达生物科技股份有限公司（临时代码）股票购买,杭州先为达生物科技股份有限公司（临时代码）股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"杭州先为达生物科技股份有限公司（临时代码）(91078)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供杭州先为达生物科技股份有限公司（临时代码）(91078)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}